Pharmacogenomics (PGx) Screening

Pharmacogenomics (PGx) Screening

Pharmacogenomics (PGx) screening is a molecular test designed to determine whether one can or cannot normally metabolize drugs that are regulated by specific genes. PGx screening enables healthcare providers to quickly optimize and refine treatment plans by revealing how a patient metabolizes different drugs based on their unique genetic polymorphisms.

Radeas keeps the collection and reporting process simple. By performing real-time, open array PCR, Radeas provides the most accurate results possible.

What Sets Radeas Apart in PGx Screening?

State-of-the-Art Molecular Diagnostic Equipment

Radeas implements real-time open array PCR technology to ensure results are delivered accurately when they’re needed most.

Wide, Comprehensive Panel

Radeas implements a comprehensive panel for PGx screening, encompassing genes with the widest range of metabolic regulation and providing insights on a broad spectrum of gene-drug interactions.

Accurate & Quick Results

Radeas PGx screening results are returned within 3 days of prior-authorization or Self Pay, with quality control checkpoints at each step of the process.